The Vital Role of Institutional Investors in Securities Class Action Lawsuits [2025]

Introduction to the Vital Role of Institutional Investors in Securities Class Action Lawsuits

Institutional investors will be leading more and more securities class actions. Securities class action lawsuits are one of the main ways public investors can seek recovery when a company (or its executives) allegedly misleads the market—through false statements, hidden risks, improper accounting, or other forms of securities fraud. In a typical case, shareholders claim they bought (or held) stock at an artificially inflated price and suffered losses when the truth came out and the stock dropped.

These lawsuits matter because they sit at the intersection of three big ideas:

1. Investor protection (compensating investors and deterring misconduct)
2. Market integrity (encouraging accurate disclosures and fair pricing)
3. Corporate governance (changing behavior inside companies after failures)

Over the last few decades, institutional investors—public pension funds, union pension funds, endowments, insurers, asset managers, mutual funds, and hedge funds—have become increasingly central in this space. They now hold a large percentage of public equity in the U.S., and they often have the largest financial stake in cases involving widely held securities.

That combination of scale and sophistication has turned many institutions into repeat players in securities litigation—especially as lead plaintiffs and as monitors pushing for governance reforms after a settlement.

Understanding the evolving role of institutional investors is not just legal trivia. It helps explain why some cases settle for more, why certain claims survive motions to dismiss while others don’t, why fee structures have changed, and how litigation can translate into real governance improvements rather than a one-time payout.

This article breaks down the “why” and “how” of institutional investor involvement in securities class actions—what changed after the PSLRA, why courts often prefer institutions as lead plaintiffs, how their participation can shape strategy and outcomes, and what trends and challenges are emerging in 2025.

For instance, there are ongoing cases like the Alexandria Real Estate Class Action Lawsuit, which underscores the importance of understanding investor rights in such scenarios. Additionally, grasping the fundamentals of securities litigation can provide valuable insights into these complex legal processes.

Moreover, instances such as the Dupixent lawsuit, where numerous lawsuits have been filed against Sanofi and Regeneron due to alleged inadequate warnings about their product, highlight how these legal battles can arise from various sectors. Similarly, the Perrigo class action lawsuit serves as another example of how misleading statements can lead to significant financial repercussions for shareholders.

In conclusion, understanding these elements not only sheds light on past cases but also prepares stakeholders for future trends and challenges in the securities litigation landscape.

The Private Securities Litigation Reform Act: A Catalyst for Institutional Investor Involvement

To understand why institutional investors play such a visible role today, you have to start with the legal architecture that pushed them forward: the Private Securities Litigation Reform Act of 1995 (PSLRA).

Why securities fraud litigation became a political and market focus

By the early-to-mid 1990s, securities class actions were already common. Critics argued some lawsuits were lawyer-driven—filed quickly after stock drops, with “professional” individual plaintiffs and minimal investor control. Supporters countered that private enforcement was essential because regulators can’t catch everything, and disclosure fraud can cause massive harm before anyone realizes what happened.

Then the 2000s delivered corporate failures that cemented public attention on disclosure and accounting fraud. Scandals like Enron and WorldCom became shorthand for:

• aggressive or deceptive accounting,
• weak auditor oversight,
• conflicted incentives, and
• poor board-level governance.

These particular collapses not only highlighted the need for strong plaintiffs in private securities litigation but also reinforced the necessity of whistleblower protections. Such protections are crucial in revealing corporate malfeasance, as seen in the aftermath of these scandals.

The broader lesson was simple: when disclosure breaks, the damage can be systemic. This is evident not just in financial sectors but also in other industries where product safety is compromised. For instance, patients using drugs like Wegovy have faced severe health repercussions, including vision-related complications. In such cases, having a dedicated Wegovy blindness lawyer could be critical in seeking justice and compensation for affected individuals.

What the PSLRA tried to do

The PSLRA was Congress’s attempt to recalibrate private securities litigation—reducing perceived abuses while preserving legitimate claims. Among its major features, the PSLRA:

• imposed heightened pleading standards for certain claims (especially scienter),
• created an automatic stay of discovery while a motion to dismiss is pending (to prevent fishing expeditions),
• encouraged courts to appoint a lead plaintiff with the largest financial interest who can adequately represent the class, and
• sought to strengthen the plaintiff’s ability to select and supervise counsel.

The overall theme was shifting power away from plaintiffs’ lawyers selecting plaintiffs—and toward investors selecting lawyers.

The Lead Plaintiff Provision: the institutional investor “on-ramp”

The PSLRA’s lead plaintiff mechanism is the single biggest reason institutions became more involved.

In simplified terms, the statute directs courts to presume that the “most adequate plaintiff” is the class member who:

1. filed a complaint or moved for appointment,
2. has the largest financial interest in the relief sought, and
3. otherwise satisfies Rule 23 typicality and adequacy.

In practice, that often points directly to institutions because:

• they frequently have the largest losses in market-wide fraud events,
• they can demonstrate sophistication and repeat experience,
• they are viewed as better positioned to supervise counsel and avoid “figurehead plaintiff” problems.

So while the PSLRA did not require institutional investors to become lead plaintiffs, it created a strong incentive and a clear procedural path. Over time, that translated into a more active institutional role—both as formal lead plaintiffs and as influential participants in the broader ecosystem of case screening, strategy, and governance demands.

Institutional Investors as Lead Plaintiffs: Advantages and Fiduciary Duties

The lead plaintiff is not a symbolic title. In a well-run case, it’s a real management role—particularly under the PSLRA’s investor-control philosophy.

What does a lead plaintiff actually do?

A lead plaintiff typically:

• selects (and negotiates with) lead counsel,
• oversees major litigation decisions (claims to emphasize, experts to retain, settlement posture),
• reviews and helps approve settlement terms,
• participates in discovery (document production, depositions, sometimes testimony),
• communicates with other large stakeholders and the court when necessary.

Courts still supervise key steps, and counsel still runs day-to-day litigation. But the lead plaintiff can meaningfully shape the direction of the case—especially when the lead plaintiff is engaged, resourced, and experienced.

Why institutions are often best suited

Institutional investors tend to stand out for three reasons: stake, sophistication, and stability.

1. Large financial interest
2. Securities fraud class actions often involve widely distributed losses. However, institutions may hold sizable positions across various strategies (index, active, long-only, factor exposures) and may have meaningful trading volume during the class period. Their claimed losses can exceed those of thousands of individuals combined.
3. For instance, consider the case of Trulicity, a medication with potential debilitating vision side effects which could lead to significant financial losses for users. Institutions holding large amounts of shares in such companies would be more affected compared to individual investors.
4. Governance and litigation sophistication
5. Many institutions—especially public pension funds and large asset owners—have teams (internal or external) that handle shareholder rights, proxy voting, and litigation oversight. Even smaller funds often have experienced advisors.
6. Consistency and credibility
7. Courts generally prefer lead plaintiffs who appear committed to the class—not motivated by side deals, not unfamiliar with basic responsibilities, and not easily influenced. Institutions can offer that credibility.

In addition to these advantages, institutional investors also play a crucial role in holding pharmaceutical companies accountable for any harmful side effects their products may cause. For example, medications like Zepbound and Mounjaro, known for their severe vision-related side effects, could face increased scrutiny from institutional investors who prioritize governance and accountability.

Furthermore, there’s a growing body of evidence linking certain medications with serious eye conditions. For instance, the use of Trulicity has been associated with macular edema, a condition that could lead to vision loss. Such insights are critical for institutional investors as they navigate the complex landscape of healthcare investments.

Fiduciary duties: why institutions can’t just ignore fraud losses

For many institutional investors, participating in litigation isn’t merely opportunistic. It can be framed as part of fiduciary responsibility.

• Public pension funds and other ERISA-covered or fiduciary-governed entities often must act prudently to protect plan assets.
• If credible evidence suggests recoverable losses due to fraud, ignoring claims may raise governance and oversight questions internally (and sometimes publicly).
• Lead plaintiff participation can be seen as an extension of stewardship: protecting beneficiaries, retirees, and long-term investors.

In other words, institutional participation is often tied to process discipline: monitoring portfolios for potential recovery opportunities, evaluating case merits, and making reasoned decisions that can be justified to boards, beneficiaries, and regulators.

Practical  to litigation

When institutions take the lead seriously, they can improve a case in ways that individual plaintiffs often can’t.

1. Monitoring counsel (real oversight)

A recurring critique of securities class actions is that they can become counsel-driven. Institutions can counterbalance that by:

• demanding clear budgets and staffing plans,
• pushing for efficient discovery,
• scrutinizing strategic choices (claims, defendants, experts),
• negotiating fee structures more aggressively.

2. Better litigation strategy and positioning

Institutional plaintiffs can help counsel focus on:

• the strongest alleged misstatements and omissions,
• the most defensible loss causation theory,
• realistic damages models,
• credible experts.

This matters because many cases are won or lost on early motion practice and expert framing—not on courtroom theatrics.

3. Increased settlement outcomes (and better settlement terms)

There is consistent discussion in the industry that institutional lead plaintiffs correlate with stronger outcomes—often attributed to tighter counsel oversight, stronger credibility, and better negotiation posture. Many practitioners cite estimates in the range of ~20% higher recoveries when institutions serve as lead plaintiffs (though results vary by case type, jurisdiction, and claim strength).

Even when the raw settlement number isn’t dramatically higher, institutions can improve:

• allocation methodology,
• governance reforms,
• transparency of settlement rationale,
• fee discipline.

Class Certification Criteria in Securities Fraud Cases: The Impact of Institutional Investor Involvement

Before a securities fraud case can proceed as a class action—and before a settlement can bind absent class members—the plaintiffs must satisfy class certification requirements under the Federal Rule of Civil Procedure 23. Class certification is often a pivotal inflection point in securities litigation because certification (or the credible threat of it) materially affects leverage.

For instance, recent cases like the Firefly Aerospace class action lawsuit, which aims to represent purchasers or acquirers of Firefly Aerospace Inc. securities, highlight how institutional investor involvement can influence the outcome. Similarly, the Baxter class action lawsuit serves as another example where class certification played a crucial role.

Institutional investors often have more resources and better access to information, which can significantly impact the class certification process. They can provide the necessary leverage to meet the stringent requirements set forth by Federal Rule of Civil Procedure 23. This was evident in the Freeport-McMoRan class action lawsuit, where institutional investors were key players.

Moreover, cases like the Primo Brands class action lawsuit further illustrate the importance of meeting class certification criteria in order to successfully represent shareholders and secure favorable outcomes. The involvement of institutional investors not only enhances the credibility of the claims but also strengthens the overall case, making it more likely for plaintiffs to achieve a successful outcome in their pursuit of justice.

Rule 23 basics: what plaintiffs must show

Most securities fraud class actions, like the Firefly Aerospace Class Action Lawsuit, seek certification under Rule 23(b)(3), which generally requires:

• Numerosity: the class is so numerous that joinder is impracticable.
• (In public company cases with thousands of investors, this is typically straightforward.)
• Commonality: common questions of law or fact exist.
• (Often satisfied because misstatements, disclosures, and market reactions are common.)
• Typicality: the lead plaintiff’s claims are typical of the class.
• (The lead plaintiff must have purchased/held during the relevant period and been harmed in a similar way.)
• Adequacy: the lead plaintiff and counsel will fairly and adequately protect the class.
• (This includes conflicts of interest, credibility, and ability to supervise counsel.)

And under Rule 23(b)(3):

• Predominance: common questions predominate over individualized ones.
• Superiority: a class action is superior to individual suits.

In securities fraud cases under Rule 10b-5, a major class certification battleground is often reliance, because reliance can be individualized. Plaintiffs frequently use the fraud-on-the-market presumption (from Basic v. Levinson) by showing the security traded in an efficient market and that the alleged misrepresentations were public and material.

For instance, Baxter Class Action Lawsuit represents a case where such principles were applied. Similarly, the MoonLake Class Action Lawsuit also exemplifies these legal standards in action.

If you find yourself needing expert legal assistance for such matters, consider reaching out to reputable firms like The Law Offices of Timothy L. Miles, which practices securities class actions and mass torts.

How institutional involvement can strengthen certification posture

Institutional investor involvement can significantly improve class certification positioning in several practical ways:

1. Stronger adequacy showing

Courts assess whether the representative plaintiff can protect the class. Institutions typically can demonstrate:

• governance structures (investment committees, boards),
• experience overseeing litigation,
• internal controls to manage conflicts,
• capacity to respond to discovery obligations.

This can reduce “adequacy attacks” that defendants sometimes raise against individual plaintiffs (e.g., unfamiliarity with allegations, inability to supervise counsel, credibility concerns).

2. Cleaner typicality narrative (in many cases)

Institutions often have trading records that support a coherent story:

• purchases during inflationary periods,
• holdings through corrective disclosures,
• losses consistent with the alleged theory.

For instance, in the Skye Bioscience Class Action Lawsuit, institutional investors could provide substantial trading records that align with the claims being made.

That said, institutions can also face typicality challenges if their trading strategies create unique issues (e.g., hedging, short positions, derivatives, or unusually timed trades). The advantage is that institutions usually have the resources to explain these issues clearly and manage them proactively.

3. Better expert framing on market efficiency and damages

Institutions frequently support robust expert work early—market efficiency analysis, event studies, and damages frameworks. This helps meet predominance and reliance-related requirements, improving the overall credibility of the class case.

4. More disciplined class definition and claims selection

A sophisticated lead plaintiff may narrow weak edges of a case—overbroad class periods, marginal statements, or questionable loss causation theories—making certification more defensible and the case more settlement-ready.

In some instances, such as with the recent Zepbound Eye Issues linked to certain medications, institutional involvement could also play a crucial role in navigating complex medical narratives within class action lawsuits.

Institutional Investors’ Role in Shaping Litigation Strategies and Overseeing Legal Counsel

Once appointed, institutional lead plaintiffs can influence the case far beyond signing verifications and showing up for depositions. In the strongest examples, they operate like a “client with leverage”—not in a hostile way, but in a way that keeps the litigation aligned with class interests.

Selecting counsel: more than picking a famous name

Under the PSLRA, lead plaintiffs typically propose lead counsel, and courts often defer to that selection if it appears reasonable.

Institutional investors can professionalize the selection process by:

• reviewing track records in similar cases (industry, accounting issues, disclosure type),
• evaluating staffing plans (who actually works the case),
• negotiating fee structures (including sliding scales tied to recovery),
• setting expectations for reporting cadence and decision points.

This matters because the lead counsel relationship affects everything that follows—motion practice, discovery posture, settlement leverage, and the quality of expert presentation.

Strategy oversight: keeping the case focused on “win conditions”

Institutions can help counsel avoid two common traps:

1. Overpleading and overreaching
2. Throwing in every possible allegation can dilute credibility and create motion-to-dismiss vulnerabilities. Sophisticated plaintiffs often push for a tighter narrative: fewer, stronger statements; clearer scienter theory; clean loss causation.
3. Inefficient discovery and “litigation sprawl”
4. Discovery can become expensive quickly. Institutions can insist on prioritization: key custodians, key timeframes, and discovery that supports core claims.

Using data analytics and AI to evaluate merits and damages (2025 reality)

By 2025, it’s increasingly common for sophisticated plaintiffs (and their counsel) to use advanced tooling to evaluate cases—especially at the intake and early framing stages. This doesn’t mean “AI decides to sue.” It usually means:

• data-driven loss estimation: trading data, event windows, and price impact modeling;
• risk screening: identifying potential fraud indicators from restatements, guidance changes, insider sales patterns, or abnormal volatility;
• document analysis acceleration: helping teams triage large document sets, flag themes, and identify contradictions faster (while still requiring human legal judgment);
• peer case benchmarking: comparing settlement ranges and outcomes across similar fact patterns and jurisdictions.

These tools can make institutions more effective clients because they can ask sharper questions early:

• What’s the core corrective disclosure?
• Is price impact measurable?
• Are damages plausible under a defensible model?
• What are the biggest risks to class certification or loss causation?

The net effect is often a more disciplined case, better aligned with what survives motions and what drives settlement value.

In scenarios where specific medications like Mounjaro or Zepbound lead to severe side effects such as vision loss or eye floaters, having a specialized lawyer becomes crucial. For instance, if one experiences vision-related complications linked to Trulicity use, consulting a Trulicity Vision Loss Lawyer could provide necessary legal support. Similarly, those affected by Zepbound’s side effects could consider pursuing a Zepbound Vision Loss Lawsuit for proper compensation.

The Impact of Institutional Investors on Settlement Outcomes and Corporate Governance Reforms Post-Litigation

Most securities class actions settle. Trials are rare, and appeals can stretch for years. That means the practical value of institutional participation often shows up in two places:

1. settlement recoveries, and
2. non-monetary governance reforms that reduce the odds of repeat behavior.

Higher settlement recoveries: what the evidence suggests

There is long-standing discussion—across academic work, practitioner commentary, and market observation—that cases with institutional lead plaintiffs tend to produce stronger recoveries. A commonly cited ballpark figure is around 20% greater recoveries when institutions serve as lead plaintiffs, though the exact number depends on how “recovery” is measured (raw settlement amount vs. percentage of estimated damages) and which cases are included.

Why might institutions improve outcomes?

• Credibility with the court and defendants: A large, sophisticated plaintiff signals seriousness and staying power.
• Better case selection: Institutions may be more selective, bringing stronger cases on average.
• Fee discipline and alignment: Negotiated fee structures can reduce agency costs and improve net recovery.
• Stronger negotiation posture: Institutions may resist low early settlements when the case is strong.
• Governance leverage: Institutions can push for reforms that defendants may prefer over additional cash—creating settlement “currency” beyond dollars.

Importantly, higher settlement outcomes don’t necessarily mean institutions demand unreasonable numbers. Often it’s about narrowing to the strongest theory and presenting it credibly—so the settlement reflects real litigation risk for defendants.

Settlements as governance tools (not just compensation)

A settlement can include corporate governance reforms such as:

• board-level changes in oversight structures,
• enhanced disclosure controls and procedures,
• risk committee formation or strengthening,
• clawback policy enhancements,
• stricter insider trading controls and blackout policies,
• compliance reporting obligations,
• independent monitors or periodic reporting (in some structures).

Not every securities class action produces meaningful reforms, and not every reform is enforceable or impactful. However, institutions are generally better positioned to push for reforms that are:

• specific (not vague “best efforts” language),
• measurable (clear deliverables),
• connected to the failure at issue (disclosure controls, audit oversight),
• durable (multi-year commitments where feasible).

This is one of the underappreciated parts of institutional participation: the lawsuit can become a governance reset mechanism, especially when the underlying allegations involve repeated disclosure breakdowns.

Trends, Challenges, and Future Outlook for Institutional Investor Participation in Securities Class Actions

Institutional participation is not uniform. Different institutions face different incentives, constraints, and reputational considerations.

Participation trends: who steps up (and why)

Public pension funds

Public pensions are among the most visible repeat lead plaintiffs. Reasons include:

• large holdings and therefore large potential losses,
• governance and stewardship mandates,
• public accountability (which can cut both ways),
• established processes for monitoring and responding to fraud events.

Union and multiemployer funds

These funds have also historically participated, sometimes actively, often with an emphasis on fiduciary recovery and governance outcomes.

Mutual funds and large asset managers

They often have enormous holdings, but participation as lead plaintiffs can be complicated by:

• conflicts (they may manage money for defendants or have business relationships),
• preference to avoid public litigation roles,
• internal policies favoring quiet recovery via claims administration rather than leadership,
• concerns about discovery burdens and reputational friction.

Hedge funds and alternative managers

Some may seek lead roles when they have significant losses and a clean posture. But they may also face defense arguments about atypicality (hedging, shorting, derivatives) depending on the case.

The result: public pensions and certain asset owners often remain the most consistent “face” of institutional lead plaintiff participation, even though asset managers may collectively control enormous voting power and holdings.

Challenges and criticisms (the real ones)

Even supporters of institutional leadership acknowledge recurring challenges:

• “Repeat player” concerns: Critics argue some institutions appear repeatedly, raising questions about whether counsel drives selections. Supporters respond that repeat experience can improve oversight and outcomes, provided the institution is genuinely engaged.
• Resource constraints: Not all institutions have staff capacity for active litigation oversight, especially smaller funds.
• Discovery burden: Producing trading records, internal communications, and governance materials can be time-consuming.
• Conflicts of interest: Business relationships, investment banking ties (for some), or overlapping roles can complicate adequacy.
• Passive investing reality: As indexing grows, institutions may be exposed to fraud events broadly—but may also be less inclined to take public leadership roles, even when losses are significant.

The best-run institutional programs address these issues through transparent governance, clear selection criteria, and documented decision-making.

Emerging proposals: influence beyond lead plaintiff status

One evolving idea is that institutional influence in securities enforcement could expand beyond the lead plaintiff mechanism—through governance and shareholder-democracy tools that operate before litigation (and sometimes independent of it). Examples of mechanisms often discussed in the broader stewardship ecosystem include:

• stronger shareholder voting and engagement on audit committee accountability, risk oversight, and disclosure practices;
• more structured stewardship escalation frameworks (engagement → votes → resolutions → litigation);
• greater transparency on how institutions decide when to seek lead plaintiff roles versus remaining passive claimants.

Whether these ideas translate into formal legal mechanisms or remain best practices will depend on regulation, market pressure, and how investors evaluate the cost-benefit of being publicly involved.

2025 outlook: what is likely to remain true

Looking forward, several realities are hard to ignore:

• Securities disclosure risks (and therefore litigation risks) are evolving—covering not just accounting, but guidance practices, operational metrics, cybersecurity incidents, AI-related claims, regulatory compliance, and complex risk disclosures.
• Institutional ownership remains dominant, which means the “largest financial interest” logic of the PSLRA will continue to point toward institutions in major cases.
• Courts will keep scrutinizing adequacy and conflicts, meaning institutional plaintiffs will need clean governance and clear documentation of their oversight role.
• Tooling (analytics, AI-assisted review, benchmarking) will keep raising the baseline for what “sophisticated plaintiff oversight” looks like.

In other words: institutional investors are not a temporary feature of securities class actions—they are becoming part of the infrastructure.

Conclusion

Securities class actions remain a key private enforcement mechanism for investor protection and market integrity. But the effectiveness of that mechanism depends heavily on who leads, how cases are managed, and whether outcomes deliver both fair compensation and meaningful deterrence.

The PSLRA’s lead plaintiff framework helped shift securities litigation toward a model where investors—especially institutional investors—can exert real control: selecting counsel, shaping strategy, supervising fees, and negotiating settlements that reflect both economic recovery and governance reform.

In 2025, the case for robust institutional involvement is still straightforward: institutions often have the largest stake, the strongest capacity to oversee complex litigation, and a fiduciary rationale to pursue recoveries for beneficiaries. When they lead responsibly, they can improve case quality, strengthen class positioning, and help ensure settlements are not just payouts, but catalysts for better corporate governance.

Supporting informed, engaged, and well-governed institutional participation isn’t just good for plaintiffs—it’s one of the most practical ways to keep securities disclosure honest and public markets worthy of trust.

FAQs (Frequently Asked Questions)

What is the significance of institutional investors in securities class action lawsuits?

Institutional investors play a vital role in securities class action lawsuits by serving as lead plaintiffs and monitors of corporate governance. Their financial stake and expertise allow them to effectively protect beneficiaries’ interests, improve litigation strategies, and enhance settlement outcomes, thereby strengthening investor protection.

How did the Private Securities Litigation Reform Act (PSLRA) influence institutional investor involvement in securities litigation?

The PSLRA of 1995 introduced the Lead Plaintiff Provision, which incentivizes institutional investors to take lead roles in securities class actions. This reform was a response to major corporate scandals like Enron and WorldCom, aiming to increase accountability and improve the effectiveness of securities fraud litigation through active institutional participation.

Why are institutional investors often considered the best suited lead plaintiffs in securities fraud cases?

Institutional investors are well-suited as lead plaintiffs due to their substantial financial stake, fiduciary duties to protect beneficiaries, and ability to monitor legal counsel closely. Their involvement enhances litigation strategy, ensures diligent oversight, and typically leads to better settlement recoveries for the class members.

How does institutional investor involvement impact class certification criteria in securities fraud lawsuits?

Institutional investors contribute significantly to meeting class certification requirements such as numerosity and commonality under Federal Rule of Civil Procedure 23. Their participation strengthens case positioning by ensuring that these criteria are effectively satisfied, which is crucial for advancing securities fraud class actions.

In what ways do institutional investors shape litigation strategies and oversee legal counsel in securities class actions?

Institutional investors actively participate in shaping litigation strategies by leveraging their expertise and resources. They select experienced legal counsel and utilize advanced tools like data analytics and artificial intelligence to accurately assess case merits and potential damages, thereby enhancing the overall effectiveness of the litigation process.

What impact do institutional investors have on settlement outcomes and corporate governance reforms following securities fraud litigation?

Evidence shows that settlements led by institutional investors yield approximately 20% greater recoveries. Beyond financial outcomes, these settlements often drive meaningful corporate governance reforms post-litigation, contributing to improved transparency, accountability, and investor protection in affected corporations.